Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled time : 05:00 save search
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
NVS | News | $97.755 0.49% 1.1M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
malaria positive treatment for novartis
Cano Health Enters Restructuring Support Agreement with a Significant Majority of its Lenders to Strengthen Financial Position
Published: 2024-02-05 (Crawled : 05:00) - prnewswire.com
CANO | $2.3 -49.13% 21K
|
Health Care and Social Assistan...
| Email alert
Add to watchlist
health financial agreement
Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
Published: 2024-01-23 (Crawled : 05:00) - prnewswire.com
SGMT | News | $4.05 -5.37% 98K
|
Health Technology
|
| O: 0.0%
H: 2.61%
C: -4.94%
positive topline denifanstat trial fascinate-2 results nash
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
Published: 2023-09-15 (Crawled : 05:00) - globenewswire.com
ARGX | $375.5 0.11% 99K
|
Health Technology
|
| O: -0.62%
H: 1.58%
C: 1.51%
chmp positive
WISeSAT AG, a Trailblazing Space Arm of WISeKey International Joins Space Innovation, Strengthening Switzerland's Position in Space-Based IoT Communication
Published: 2023-09-15 (Crawled : 05:00) - globenewswire.com
LAES | News | $1.27 1.6% 480K
|
n/a
|
| O: -2.22%
H: 3.69%
C: -8.81%
WKEY | News | $2.14 3.9K
|
Technology Services
|
| O: 0.82%
H: 0.0%
C: -6.07%
arm international iot space communication
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Published: 2023-09-07 (Crawled : 05:00) - globenewswire.com
PFE | News 4 | $26.25 -0.27% 9.9M
|
Health Technology
|
| O: 0.29%
H: 0.49%
C: -0.55%
candidate disease report vaccine positive valneva results phase 2
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-21 (Crawled : 05:00) - globenewswire.com
TAK | News | $13.215 -1.23% 420K
|
Health Technology
|
| O: -0.4%
H: 0.6%
C: 0.47%
EXEL | $23.63 1.46% 560K
|
Health Technology
|
| O: 0.28%
H: 1.32%
C: 0.99%
ntact-02 positive cancer trial results
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration
Published: 2023-08-03 (Crawled : 05:00) - globenewswire.com
ADXN | $18.74 7.9K
|
Health Technology
|
| O: 7.34%
H: 4.39%
C: -3.51%
positive research collaboration program
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Published: 2023-07-17 (Crawled : 05:00) - globenewswire.com
ZLAB | $15.61 3.24% 190K
|
Health Technology
|
| O: 8.26%
H: 0.5%
C: -8.33%
ARGX | $375.5 0.11% 99K
|
Health Technology
|
| O: 25.96%
H: 4.43%
C: 1.45%
report vyvgart positive topline study
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
Published: 2023-07-17 (Crawled : 05:00) - globenewswire.com
ARGX | $375.5 0.11% 99K
|
Health Technology
|
| O: 25.96%
H: 4.43%
C: 1.45%
vyvgart positive topline study
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Published: 2023-06-30 (Crawled : 05:00) - globenewswire.com
GNFT | $3.4449 3.3K
|
Health Technology
|
| O: 0.0%
H: 0.99%
C: -12.59%
elative rare liver disease positive trial results
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
Published: 2023-05-31 (Crawled : 05:00) - globenewswire.com
SNY | News | $46.615 -2.25% 730K
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
cd40 disease antibody positive sclerosis show
Positive Stock Market Observations For The Week Ahead – Forbes
Published: 2023-01-09 (Crawled : 05:00) - spacfeed.com
ATLXD | $8.1 0
|
n/a
|
| O: -1.34%
H: 15.51%
C: 10.2%
LTUM | $0.0351 410K
|
Mining, Quarrying, and Oil and ...
|
| O: -2.94%
H: 12.36%
C: -1.12%
week positive market
Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients with ROS1-Positive NSCLC
Published: 2022-10-28 (Crawled : 05:00) - prnewswire.com
NUVL | $68.245 0.95% 200K
|
|
| O: 42.89%
H: 0.0%
C: 0.0%
nvl-520 trial potential phase 1
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
Published: 2022-04-04 (Crawled : 05:00) - prnewswire.com
IONS | $42.1 0.62% 290K
|
Health Technology
|
| O: 0.1%
H: 0.41%
C: -0.54%
cardiology positive phase 2b
Red Rock Resorts, Inc. appoints Scott Kreeger to position of President
Published: 2022-03-01 (Crawled : 05:00) - prnewswire.com
RRR | $58.7 -0.39% 110K
|
Consumer Services
|
| O: 0.89%
H: 0.42%
C: -5.09%
positive
Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021
Published: 2021-09-29 (Crawled : 05:00) - globenewswire.com
CLDX | $37.29 -1.27% 130K
|
Health Technology
|
| O: 0.0%
H: 1.03%
C: -2.59%
phase 1 positive phase 1b urticaria phase 2b
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Published: 2021-07-30 (Crawled : 05:00) - biospace.com/
BGNE | $142.065 2.21% 100K
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
treatment positive results topline brukinsa leukemia phase 3 trial
Chindata Group Records Sixth Consecutive Quarter of Positive Adjusted Net Income in Q4, totaling Adjusted Net Income of RMB174.9 million in 2020
Published: 2021-03-25 (Crawled : 05:00) - prnewswire.com
CD | $8.45 1.3% 12M
|
Technology Services
|
| O: 0.69%
H: 4.13%
C: 3.31%
positive
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $1.88 60.68% 98M
|
AMST | $3.2 60.0% 63M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.